After treatment with DAC, they found that lymphoma cells were more susceptible to being killed by CD19 CAR-T cells because of the increased expression of surface antigen density, and two patients with r/r lymphoma treated with DAC and CAR-T cells both achieved CR. Here, CD19 is linked to lymphoma.